Literature DB >> 33936519

Improving Anticoagulant Treatment Strategies of Atrial Fibrillation Using Reinforcement Learning.

Lei Zuo1, Xin Du2,3, Wei Zhao1, Chao Jiang2, Shijun Xia2, Liu He2, Rong Liu3, Ribo Tang2, Rong Bai2, Jianzeng Dong2,4, Xingzhi Sun1, Gang Hu1, Guotong Xie1, Changsheng Ma2.   

Abstract

In this paper, we developed a personalized anticoagulant treatment recommendation model for atrial fibrillation (AF) patients based on reinforcement learning (RL) and evaluated the effectiveness of the model in terms of short-term and long-term outcomes. The data used in our work were baseline and follow-up data of 8,540 AF patients with high risk of stroke, enrolled in the Chinese Atrial Fibrillation Registry (CAFR) study during 2011 to 2018. We found that in 64.98% of patient visits, the anticoagulant treatment recommended by the RL model were concordant with the actual prescriptions of the clinicians. Model-concordant treatments were associated with less ischemic stroke and systemic embolism (SSE) event compared with non-concordant ones, but no significant difference on the occurrence rate of major bleeding. We also found that higher proportion of model-concordant treatments were associated with lower risk of death. Our approach identified several high-confidence rules, which were interpreted by clinical experts. ©2020 AMIA - All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33936519      PMCID: PMC8075452     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  16 in total

1.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2019-01-28       Impact factor: 24.094

2.  Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score.

Authors:  Rachel M Kaplan; Jodi Koehler; Paul D Ziegler; Shantanu Sarkar; Steven Zweibel; Rod S Passman
Journal:  Circulation       Date:  2019-09-30       Impact factor: 29.690

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld
Journal:  Eur J Cardiothorac Surg       Date:  2016-09-23       Impact factor: 4.191

4.  Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries.

Authors:  Leif Friberg; Fariborz Tabrizi; Anders Englund
Journal:  Eur Heart J       Date:  2016-03-16       Impact factor: 29.983

5.  Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis.

Authors:  Gregory Y H Lip; Felicita Andreotti; Laurent Fauchier; Kurt Huber; Elaine Hylek; Eve Knight; Deirdre Lane; Marcel Levi; Francisco Marín; Gualtiero Palareti; Paulus Kirchhof
Journal:  Thromb Haemost       Date:  2011-11-02       Impact factor: 5.249

6.  Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.

Authors:  Craig I Coleman; W Frank Peacock; Thomas J Bunz; Mark J Alberts
Journal:  Stroke       Date:  2017-06-27       Impact factor: 7.914

Review 7.  Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.

Authors:  Freek W A Verheugt; Christopher B Granger
Journal:  Lancet       Date:  2015-03-14       Impact factor: 79.321

8.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.

Authors:  A D Krahn; J Manfreda; R B Tate; F A Mathewson; T E Cuddy
Journal:  Am J Med       Date:  1995-05       Impact factor: 4.965

9.  The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care.

Authors:  Matthieu Komorowski; Leo A Celi; Omar Badawi; Anthony C Gordon; A Aldo Faisal
Journal:  Nat Med       Date:  2018-10-22       Impact factor: 53.440

10.  Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study.

Authors:  Jeff S Healey; Jonas Oldgren; Michael Ezekowitz; Jun Zhu; Prem Pais; Jia Wang; Patrick Commerford; Petr Jansky; Alvaro Avezum; Alben Sigamani; Albertino Damasceno; Paul Reilly; Alex Grinvalds; Juliet Nakamya; Akinyemi Aje; Wael Almahmeed; Andrew Moriarty; Lars Wallentin; Salim Yusuf; Stuart J Connolly
Journal:  Lancet       Date:  2016-08-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.